Cingulate (CINGW) Tax Provisions (2022 - 2026)
Cingulate's (CINGW) quarterly Tax Provisions came in at -$1.2 million in Q2 2026, down 18.02% on a YoY basis from -$1.5 million in Q2 2025, and up 6.52% quarter-over-quarter from -$1.3 million in Q4 2025.
Analysis
Cingulate (CINGW) Tax Provisions (2022 - 2026) Analysis & Trends
Cingulate (CINGW) has reported Tax Provisions for 5 consecutive years, with -$1.2 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Tax Provisions fell 18.02% year-over-year to -$1.2 million; the trailing twelve-month figure through Jun 2026 stood at -$5.1 million (down 27.87% YoY), and the FY2025 full-year result was -$4.7 million, down 35.56% from the prior year.
- Tax Provisions rose to -$1.2 million in Q2 2026 per CINGW's latest filing, from -$1.3 million in the prior quarter.
- Across five years, Tax Provisions topped out at -$588266.0 in Q1 2024 and bottomed at -$1.5 million in Q3 2025.
- Historically, Tax Provisions has averaged -$1.1 million across 5 years, with a median of -$1.0 million in 2022.
- The sharpest annual moves came in 2024 and 2025: Tax Provisions jumped 48.9% in 2024, then slumped 77.94% in 2025.
- Over 5 years, Tax Provisions stood at -$978229.0 in 2022, then sank by 48.27% to -$1.5 million in 2023, then increased by 9.78% to -$1.3 million in 2024, then declined by 0.79% to -$1.3 million in 2025, then grew by 6.52% to -$1.2 million in 2026.
- According to Business Quant data, Tax Provisions over the past three periods registered -$1.2 million, -$1.3 million, and -$1.5 million for Q2 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 644.70 Bn | 623.94 Bn | 17.26 Bn | 1.21 Bn |
| 2 | AbbVie | 441.16 Bn | 434.59 Bn | 12.70 Bn | 662.00 Mn |
| 3 | Merck | 364.92 Bn | 357.78 Bn | 12.21 Bn | 654.00 Mn |
| 4 | Novartis Ag | 266.48 Bn | 258.79 Bn | 11.24 Bn | -1.01 Bn |
| 5 | Pfizer | 159.03 Bn | 147.33 Bn | 10.94 Bn | -407.00 Mn |
| 6 | Sanofi | 52.53 Bn | 45.15 Bn | 10.79 Bn | -524.23 Mn |
| 7 | Revolution Medicines | 44.20 Bn | 44.20 Bn | - | - |
| 8 | Incyte | 25.27 Bn | 20.74 Bn | 1.57 Bn | 165.91 Mn |
| 9 | United Therapeutics | 21.44 Bn | 18.78 Bn | 683.80 Mn | 39.70 Mn |
| 10 | Cingulate | 100,214.03 | 100,214.03 | - | -1.23 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -1.23 Mn |
| Dec 31, 2025 | -1.32 Mn |
| Sep 30, 2025 | -1.54 Mn |
| Jun 30, 2025 | -1.04 Mn |
| Mar 31, 2025 | -798,576.00 |
| Dec 31, 2024 | -1.31 Mn |
| Sep 30, 2024 | -866,387.00 |
| Jun 30, 2024 | -709,986.00 |
| Mar 31, 2024 | -588,266.00 |
| Dec 31, 2023 | -1.45 Mn |
| Sep 30, 2023 | -1.26 Mn |
| Jun 30, 2023 | -1.39 Mn |
| Mar 31, 2023 | -841,026.00 |
| Dec 31, 2022 | -978,229.00 |
| Sep 30, 2022 | -845,722.00 |
| Jun 30, 2022 | -848,475.00 |
| Mar 31, 2022 | -1.04 Mn |